Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.

Oncologist. 2013;18(5):543-8. doi: 10.1634/theoncologist.2012-0435. Epub 2013 May 8.

2.

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.

Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T.

Ann Surg Oncol. 2015 Apr;22(4):1153-9. doi: 10.1245/s10434-014-4225-1. Epub 2014 Oct 31.

3.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM.

BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199.

4.

CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.

Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB.

Eur Radiol. 2017 Jul;27(7):3104-3116. doi: 10.1007/s00330-016-4632-8. Epub 2016 Nov 28.

PMID:
27896469
5.

Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.

Nanda RH, El-Rayes B, Maithel SK, Landry J.

J Surg Oncol. 2015 Jun;111(8):1028-34. doi: 10.1002/jso.23921. Epub 2015 Jun 12.

PMID:
26073887
6.

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.

Oncologist. 2014 Mar;19(3):266-74. doi: 10.1634/theoncologist.2013-0273. Epub 2014 Feb 25.

7.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG.

Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.

8.

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.

Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ.

J Surg Oncol. 2018 Nov;118(6):1021-1026. doi: 10.1002/jso.25233. Epub 2018 Sep 27.

9.

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20. doi: 10.1245/s10434-015-4851-2. Epub 2015 Sep 8.

PMID:
26350368
10.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

11.

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.

Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM.

Chemotherapy. 2013;59(4):273-9. doi: 10.1159/000356158. Epub 2014 Jan 18.

PMID:
24457620
12.

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J.

Br J Cancer. 2016 Mar 29;114(7):737-43. doi: 10.1038/bjc.2016.45.

13.

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.

Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J.

Med Oncol. 2013 Mar;30(1):361. doi: 10.1007/s12032-012-0361-2. Epub 2012 Dec 28. Review.

PMID:
23271209
14.

Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Lakatos G, Petranyi A, Szűcs A, Nehéz L, Harsanyi L, Hegyi P, Bodoky G.

Pathol Oncol Res. 2017 Oct;23(4):753-759. doi: 10.1007/s12253-016-0176-0. Epub 2017 Jan 6.

PMID:
28062950
15.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC.

Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4.

16.

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S.

Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.

PMID:
21778770
17.

FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2014 Dec;13(4):232-8. doi: 10.1016/j.clcc.2014.09.005. Epub 2014 Sep 21.

PMID:
25442814
18.

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N.

J Surg Oncol. 2013 Sep;108(4):236-41. doi: 10.1002/jso.23392.

19.

[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].

Bai X, Su R, Ma T, Shen S, Li G, Lou J, Gao S, Que R, Yuan Y, Yu R, Wei Q, Liang T.

Zhonghua Wai Ke Za Zhi. 2016 Apr 1;54(4):270-5. doi: 10.3760/cma.j.issn.0529-5815.2016.04.006. Chinese.

PMID:
27029201
20.

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ.

Br J Cancer. 2016 Sep 6;115(6):649-54. doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28.

Supplemental Content

Support Center